Canaccord Genuity Believes GenMark (NASDAQ: GNMK) Won’t Stop Here

By Jason Carr

Canaccord Genuity analyst Mark Massaro reiterated a Buy rating on GenMark (NASDAQ: GNMK) today and set a price target of $17. The company’s shares opened today at $13.02, close to its 52-week high of $13.67.

According to, Massaro is a 5-star analyst with an average return of 12.2% and a 61.6% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Meridian Bioscience Inc, and Quest Diagnostics Inc.

Currently, the analyst consensus on GenMark is Strong Buy and the average price target is $17, representing a 30.6% upside.

In a report released today, Needham also reiterated a Buy rating on the stock with a $17 price target.

The company has a one year high of $13.67 and a one year low of $7.82. Currently, GenMark has an average volume of 233.1K.

Based on the recent corporate insider activity of 96 insiders, corporate insider sentiment is negative on the stock. Most recently, in March 2017, Jon Faiz Kayyem, the SVP R&D of GNMK sold 311 shares for a total of $3,788.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

GenMark Diagnostics, Inc. is a molecular diagnostics company. The firm focuses on the development and commercializing of its its proprietary eSensor detection technology. It also manufactures, sells, and supports instruments and molecular tests. The company was founded by Jon Faiz Kayyem on February 12, 2010 and is headquartered in Carlsbad, CA.